{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/gonorrhoea/diagnosis/confirmation-of-diagnosis/","result":{"pageContext":{"chapter":{"id":"e568c796-6f9e-5513-a973-7efca33d5b62","slug":"confirmation-of-diagnosis","fullItemName":"Confirmation of diagnosis","depth":2,"htmlHeader":"<!-- begin field 475b596a-9ab4-4700-ab13-535332f114f2 --><h2>How should I confirm a diagnosis of gonorrhoea?</h2><!-- end field 475b596a-9ab4-4700-ab13-535332f114f2 -->","summary":"","htmlStringContent":"<!-- begin item 393f22c7-f8b6-4abc-ae08-a254e8045de1 --><!-- begin field 91bc511b-7e30-4f34-8412-713d088f658c --><ul><li>Ideally, refer all people with suspected gonorrhoea to a genito-urinary medicine (GUM) clinic or other local specialist sexual health service for confirmation of diagnosis.</li><li>If the person is unwilling, or unable, to attend a GUM clinic or other local specialist sexual health service, arrange a nucleic acid amplification test (NAAT) for the presence of <em>Neisseria Gonorrhoea</em> in line with local procedures and protocols.<ul><li>Tests should be taken no earlier than 3 days after sexual contact with an infected person.</li><li><strong>In women</strong>, a vulvovaginal swab (which may be self-taken) should be used. <ul><li>For more information on taking an endocervical swab, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/vaginal-discharge/\">Vaginal discharge</a>.</li></ul></li><li><strong>In men</strong>, a first pass urine specimen should be used.</li></ul></li><li>A culture should be taken in all people who are NAAT positive for gonorrhoea before prescribing antibiotics to test for susceptibility and identify resistant strains.</li><li>In both men and women, sites sampled for swabs should be mucosal sites associated with symptoms, and sites related to the type of sexual activity reported.</li></ul><!-- end field 91bc511b-7e30-4f34-8412-713d088f658c --><!-- end item 393f22c7-f8b6-4abc-ae08-a254e8045de1 -->","topic":{"id":"8aeba2d1-9f1a-5428-a119-41fa94223706","topicId":"4b4cdbb6-97a0-4b13-a04c-d857b72bcddf","topicName":"Gonorrhoea","slug":"gonorrhoea","lastRevised":"Last revised in November 2020","chapters":[{"id":"803822d1-16b6-5c36-b47d-9a6e8e236c06","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"b8d98590-b989-554f-8ccb-804279dab0d2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"4ac6e3b9-f31e-5367-b177-171c1cd87bd7","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"41812e79-dbe3-5991-8344-05de91dff192","slug":"changes","fullItemName":"Changes"},{"id":"bbabf43d-27dd-5795-b02b-9891c7e9e7ca","slug":"update","fullItemName":"Update"}]},{"id":"cd231f06-b527-5de3-a8cb-277fd6f84587","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"858e0da7-8025-510b-ac87-1055c9b510e0","slug":"goals","fullItemName":"Goals"},{"id":"b9efda8e-7814-5479-af6b-1272844f3546","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"874bc02c-2022-584f-bc91-b99489f3ac6c","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"17fcc032-43d9-5c38-b19b-e10bef0648f1","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"1033f77b-d5e5-5700-b7f9-f314bb1daef3","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"11e8f7de-1c3f-5692-a9e4-f2c1645e1023","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"f889ee27-2135-5f9e-b131-fb46452febe4","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"55283c6e-a75b-5deb-8827-406245e897ff","slug":"definition","fullItemName":"Definition"},{"id":"cf7e0416-d49c-57de-8063-ebf536922bcc","slug":"prevalence","fullItemName":"Prevalence"},{"id":"6c929d32-5621-5a53-9e9b-63a3e1523e20","slug":"prognosis","fullItemName":"Prognosis"},{"id":"1196a066-1188-5938-b1d3-932dd0ffc403","slug":"complications","fullItemName":"Complications"}]},{"id":"acc7ed62-ebd4-506d-a105-4b05f6f7e38a","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"a9a1ae79-f8a2-59e3-a720-8207d27eee47","slug":"assessment","fullItemName":"Assessment"},{"id":"0ee9cef7-bd86-583b-9d57-f5d8f9a5d6d0","slug":"signs-symptoms-in-a-man","fullItemName":"Signs and symptoms in a man"},{"id":"9b460f20-3213-5956-896f-ccc5156c9d32","slug":"signs-symptoms-in-a-woman","fullItemName":"Signs and symptoms in a woman"},{"id":"e568c796-6f9e-5513-a973-7efca33d5b62","slug":"confirmation-of-diagnosis","fullItemName":"Confirmation of diagnosis"},{"id":"44933641-db44-5935-9459-ea8e78869d57","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"e0f6f6d2-d4a8-5801-b817-0588e8540a04","slug":"possible-sexual-abuse","fullItemName":"Possible sexual abuse"}]},{"id":"d05b0423-47bb-53df-ab5a-8730ca4d3325","fullItemName":"Management","slug":"management","subChapters":[{"id":"171cfead-d784-5eab-b668-c3fe9015a93a","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"98eac615-b29a-5de3-a795-37b42615eb61","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"9c11c59e-3407-52b9-a870-aed88dcd9236","slug":"cephalosporins-ceftriaxone-or-cefixime","fullItemName":"Cephalosporins (ceftriaxone or cefixime)"},{"id":"af56affe-2e43-5ee7-b94a-333ead3b8efa","slug":"quinolones-ciprofloxacin-or-ofloxacin","fullItemName":"Quinolones (ciprofloxacin or ofloxacin)"},{"id":"caa85d19-223f-5ca5-ae12-313a1b2462d1","slug":"azithromycin","fullItemName":"Azithromycin"}]},{"id":"39f7e7ee-870b-55c8-9cd9-55320d487f24","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"05886abb-50fd-51e9-b3c2-e2e99ad9b241","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"bdd6db63-13f7-5183-a3a2-63b619818fb3","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0d44a69c-3824-5509-a756-cda3bc1bd50a","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"e5526ef2-c93a-595d-a0c1-8068bad91f10","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"0092236d-21ec-5777-85c0-6e95f9962a15","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"8791b380-0e55-5489-987e-5db590030323","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"bc36d12c-c9a8-5970-8b4b-74304413a1f0","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"acc7ed62-ebd4-506d-a105-4b05f6f7e38a","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"04611e4f-b087-51f8-a119-e1a747ba72be","slug":"nucleic-acid-amplification-testing-naat","fullItemName":"Nucleic acid amplification testing (NAAT)","depth":3,"htmlHeader":"<!-- begin field c1833774-8244-4ad6-a1be-a78401020372 --><h3>Nucleic acid amplification testing (NAAT)</h3><!-- end field c1833774-8244-4ad6-a1be-a78401020372 -->","summary":null,"htmlStringContent":"<!-- begin item 8f5066ef-123e-4d0c-a2f0-a7840101fe3f --><!-- begin field 494f7fba-9be2-483a-ad9c-a78401020372 --><ul><li>Nucleic acid amplification testing (NAAT) amplifies and detects nucleic acid sequences that are specific for the organism being detected.</li><li>NAATs are extremely sensitive and can detect very small amounts of DNA or ribosomal RNA (rRNA).<ul><li>However, detection does not mean the organism is viable. </li></ul></li><li>NAATs show high sensitivity (more than 96%) in both symptomatic and asymptomatic infection, which is higher than for culture (85-95%). NAAT has an equivalent senitivity in urine and urethral swab specimens from men and in vaginal and endocervical swabs from women.<ul><li>Sensitivity in female urine is significantly lower — urine is not the optimal specimen in women.</li></ul></li><li>NAATs, however, do not provide information on antimicrobial susceptibility.<ul><li>Culture is essential for monitoring antimicrobial susceptibility and to detect emerging resistance to therapy.</li></ul></li></ul><!-- end field 494f7fba-9be2-483a-ad9c-a78401020372 --><!-- end item 8f5066ef-123e-4d0c-a2f0-a7840101fe3f -->","subChapters":[]},{"id":"48321f6c-3ac1-5cf8-8703-11d7faa9c71b","slug":"basis-for-recommendation-c16","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field 01c032cd-8cb5-432b-8278-352680bea265 --><h3>Basis for recommendation</h3><!-- end field 01c032cd-8cb5-432b-8278-352680bea265 -->","summary":null,"htmlStringContent":"<!-- begin item c163dce2-04ff-42fd-99ec-05c1380f158c --><!-- begin field a0d1165f-2398-4b79-be6c-80d2b20b8e3e --><p>These recommendations are based on the British Association for Sexual Health and HIV (BASHH) <em>UK national guideline for the management of gonorrhoea in adults </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">BASHH, 2011</a>], and <em>United Kingdom national guideline for gonorrhoea testing</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">BASHH, 2012</a>], a joint guideline with the Royal College of General Practitioners <em>Sexually transmitted infections in primary care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">RCGP, 2013</a>], the Public Health England (PHE) <em>Guidance for the detection of gonorrhoea in England</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">PHE, 2014</a>] and the US Centers for Disease Control and Prevention (CDC) <em>Recommendations for the laboratory-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">CDC, 2014</a>].</p><!-- end field a0d1165f-2398-4b79-be6c-80d2b20b8e3e --><!-- end item c163dce2-04ff-42fd-99ec-05c1380f158c -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}